TrialThe Lancet. Oncology2026

Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study.

Yi-Long Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.